Wires·
Standing by — next sweep in ~12 min.
Markets
Dow+0.79%Russell 2000-0.45%Nasdaq+2.38%S&P 500+1.59%VXX-4.29%IEF+0.02%GLD-1.34%SLV-1.12%USO+1.35%UUP-0.28%Dow+0.79%Russell 2000-0.45%Nasdaq+2.38%S&P 500+1.59%VXX-4.29%IEF+0.02%GLD-1.34%SLV-1.12%USO+1.35%UUP-0.28%

BDX

Becton Dickinson & CompanyHealth Careinsider_universe
Last close $154.90Jun 28, 2026
Day −0.66%

Currently held

  • Agent 5 — Dip Buyer (Evolving)long
    12 sh @ $143.47 · stop $131.99
    +$123.48 unrealized
  • Agent 8 — Dip Buyer (Peer-Aware)long
    8 sh @ $143.47 · stop $131.99
    +$82.32 unrealized

Everything we've seen

  1. ·Jun 29, 3:45 PMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  2. ·Jun 29, 3:30 PMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  3. ·Jun 29, 3:17 PMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  4. ·Jun 29, 3:02 PMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  5. ·Jun 29, 2:47 PMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  6. ·Jun 29, 2:31 PMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  7. ·Jun 29, 2:16 PMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  8. ·Jun 29, 2:01 PMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  9. ·Jun 29, 1:46 PMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  10. ·Jun 29, 1:31 PMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  11. ·Jun 29, 1:16 PMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  12. ?Jun 29, 1:11 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BDX is down 1.64% intraday, which is a moderate but not outsized move. There are no recent headlines to explain the move, which means it could be sector rotation or quiet institutional selling rather than a catalytic event. The macro context shows 10Y inflation expectations (T10YIE) at 2.1σ below trend, which is a low-rate-expectation environment — generally modestly supportive for long-duration sensitive sectors, which could include medtech/healthcare names like BDX, suggesting a slight headwind to further downside continuation. With 154 minutes remaining there is ample time for the move to continue, but also ample time for a mean-reversion bounce given no clear news catalyst. Volume data is unavailable, adding uncertainty. The move magnitude (1.64%) is real but not extreme enough to signal high-conviction institutional distribution. Balancing moderate momentum evidence against a mildly supportive macro backdrop and no confirming catalyst, this sits at the borderline. Assigning 0.50 — the system's intended threshold for borderline reads — reflecting no strong reason to fade but also no strong confirmation of continuation.

  13. !Jun 29, 1:11 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    BDX is down 1.64% intraday, which is a moderate but not outsized move. There are no recent headlines to explain the move, which means it could be sector rotation or quiet institutional selling rather than a catalytic event. The macro context shows 10Y inflation expectations (T10YIE) at 2.1σ below trend, which is a low-rate-expectation environment — generally modestly supportive for long-duration sensitive sectors, which could include medtech/healthcare names like BDX, suggesting a slight headwind to further downside continuation. With 154 minutes remaining there is ample time for the move to continue, but also ample time for a mean-reversion bounce given no clear news catalyst. Volume data is unavailable, adding uncertainty. The move magnitude (1.64%) is real but not extreme enough to signal high-conviction institutional distribution. Balancing moderate momentum evidence against a mildly supportive macro backdrop and no confirming catalyst, this sits at the borderline. Assigning 0.50 — the system's intended threshold for borderline reads — reflecting no strong reason to fade but also no strong confirmation of continuation.

  14. ·Jun 29, 1:02 PMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  15. ·Jun 29, 12:47 PMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  16. ·Jun 29, 12:32 PMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  17. ·Jun 29, 12:17 PMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  18. ·Jun 29, 12:02 PMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  19. ·Jun 29, 11:47 AMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  20. ·Jun 29, 11:32 AMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  21. ·Jun 29, 11:17 AMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  22. ·Jun 29, 11:03 AMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  23. ·Jun 29, 10:48 AMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  24. ·Jun 29, 10:33 AMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  25. ·Jun 29, 10:18 AMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  26. ·Jun 29, 10:03 AMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  27. !Jun 29, 9:51 AMsignal

    Agent 6 — Options Momentum — insufficient_capital

  28. ·Jun 29, 9:48 AMstreamnews

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  29. !Jun 29, 7:06 AMsignal

    Agent 6 — Options Momentum — insufficient_capital

  30. ❖Jun 27, 2:28 AMnewsvia finnhub

    Best Dividend Aristocrats: June 2026

    Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.

  31. ?Jun 26, 3:40 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BDX is up 2.50% with only 5 minutes remaining until forced close. The extremely limited time remaining is the dominant factor here — even strong momentum cannot reasonably be expected to extend meaningfully in a 5-minute window, and any continued move would be too small relative to the +3% profit target to be actionable. The macro context (low T10YIE, 1.9σ below trend) is modestly supportive of defensive/healthcare names like BDX as a long-duration sensitive sector, but this is a weak tailwind. No news catalyst is present to drive a late surge. The move itself (2.50%) reflects real conviction, but with 5 minutes to close, the probability of meaningful continuation is low — the risk of a last-minute fade or profit-taking into the close outweighs the upside. Probability set below 0.5 solely due to time constraint.

  32. !Jun 26, 3:40 PMsignalseverity 0.03

    Agent 7 — Day Trader — day_trade_skipped

    BDX is up 2.50% with only 5 minutes remaining until forced close. The extremely limited time remaining is the dominant factor here — even strong momentum cannot reasonably be expected to extend meaningfully in a 5-minute window, and any continued move would be too small relative to the +3% profit target to be actionable. The macro context (low T10YIE, 1.9σ below trend) is modestly supportive of defensive/healthcare names like BDX as a long-duration sensitive sector, but this is a weak tailwind. No news catalyst is present to drive a late surge. The move itself (2.50%) reflects real conviction, but with 5 minutes to close, the probability of meaningful continuation is low — the risk of a last-minute fade or profit-taking into the close outweighs the upside. Probability set below 0.5 solely due to time constraint.

  33. ❖Jun 26, 1:55 PMnewsvia finnhub

    Dividend Champion, Contender, And Challenger Highlights: Week Of June 28

    A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read it here.

  34. !Jun 26, 12:49 PMsignal

    Agent 6 — Options Momentum — insufficient_capital

  35. !Jun 26, 11:51 AMsignal

    Agent 6 — Options Momentum — insufficient_capital

  36. !Jun 26, 10:48 AMsignal

    Agent 6 — Options Momentum — insufficient_capital

  37. !Jun 26, 10:35 AMsignal

    Agent 6 — Options Momentum — insufficient_capital

  38. !Jun 26, 10:21 AMsignal

    Agent 6 — Options Momentum — insufficient_capital

  39. !Jun 26, 9:50 AMsignal

    Agent 6 — Options Momentum — insufficient_capital

  40. ?Jun 26, 9:36 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BDX is up ~2.06% with no attributable headline, suggesting institutional flow or sector rotation rather than a news-driven spike. The macro context shows 10Y inflation expectations (T10YIE) at 1.9σ below trend, which is modestly favorable for long-duration sensitive and defensive healthcare names like BDX — lower inflation expectations can support valuation multiples. However, at 370 minutes remaining (early-to-mid session), there is ample time but also ample time for a fade if the move was front-loaded. Without a clear catalyst or confirmation of sustained volume, this is a moderate momentum read. No reversal signals are visible, no negative headlines, and the macro backdrop is mildly supportive. Assigning a modest continuation probability above the 0.5 threshold, reflecting ordinary momentum with no strong reason to fade.

  41. !Jun 26, 9:36 AMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    BDX is up ~2.06% with no attributable headline, suggesting institutional flow or sector rotation rather than a news-driven spike. The macro context shows 10Y inflation expectations (T10YIE) at 1.9σ below trend, which is modestly favorable for long-duration sensitive and defensive healthcare names like BDX — lower inflation expectations can support valuation multiples. However, at 370 minutes remaining (early-to-mid session), there is ample time but also ample time for a fade if the move was front-loaded. Without a clear catalyst or confirmation of sustained volume, this is a moderate momentum read. No reversal signals are visible, no negative headlines, and the macro backdrop is mildly supportive. Assigning a modest continuation probability above the 0.5 threshold, reflecting ordinary momentum with no strong reason to fade.

  42. !Jun 26, 9:35 AMsignal

    Agent 6 — Options Momentum — insufficient_capital

  43. !Jun 26, 9:17 AMsignal

    Agent 6 — Options Momentum — insufficient_capital

  44. !Jun 26, 7:03 AMsignal

    Agent 6 — Options Momentum — insufficient_capital

  45. !Jun 25, 5:47 PMsignal

    Agent 6 — Options Momentum — insufficient_capital

  46. !Jun 25, 5:31 PMsignal

    Agent 6 — Options Momentum — insufficient_capital

  47. !Jun 25, 5:16 PMsignal

    Agent 6 — Options Momentum — insufficient_capital

  48. !Jun 25, 5:06 PMsignal

    Agent 6 — Options Momentum — insufficient_capital

  49. !Jun 25, 4:47 PMsignal

    Agent 6 — Options Momentum — insufficient_capital

  50. !Jun 25, 4:32 PMsignal

    Agent 6 — Options Momentum — insufficient_capital

  51. !Jun 25, 4:21 PMsignal

    Agent 6 — Options Momentum — insufficient_capital

  52. !Jun 25, 3:47 PMsignal

    Agent 6 — Options Momentum — insufficient_capital

  53. !Jun 25, 3:33 PMsignal

    Agent 6 — Options Momentum — insufficient_capital

  54. !Jun 25, 3:17 PMsignal

    Agent 6 — Options Momentum — insufficient_capital

  55. !Jun 25, 2:48 PMsignal

    Agent 6 — Options Momentum — insufficient_capital

  56. !Jun 25, 2:35 PMsignal

    Agent 6 — Options Momentum — insufficient_capital

  57. !Jun 25, 2:20 PMsignal

    Agent 6 — Options Momentum — insufficient_capital

  58. !Jun 25, 1:47 PMsignal

    Agent 6 — Options Momentum — insufficient_capital

  59. !Jun 25, 1:35 PMsignal

    Agent 6 — Options Momentum — insufficient_capital

  60. ❖Jun 24, 8:52 AMnewsvia finnhub

    How Are Emerging Markets Supporting Abbott's EPD Momentum?

    ABT's Emerging Markets drive EPD growth, with strong branded generics demand, biosimilar expansion and new approvals boosting momentum.

  61. ?Jun 23, 11:05 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BDX is up 2.39% today, a meaningful move driven by a mix of signals. The Vizient Innovative Technology Contract for CentroVena One is a positive catalyst supporting the move. However, the voluntary recall of skin preparation products is a meaningful headwind that likely dampened what could have been a stronger rally — the net positive price action suggests the contract win is being weighted more heavily by the market. Macro context is modestly supportive: below-trend inflation expectations (T10YIE at 1.7σ below 24-month trend) favor long-duration sensitive and defensive healthcare names like BDX, as lower real rates reduce discount pressure on stable cash flow businesses. With 280 minutes remaining, there is ample time for continuation. That said, the recall overhang introduces uncertainty and could invite late-session selling or profit-taking as participants reassess the liability exposure. No strong reversal signal is present, and the move appears grounded in real news flow rather than a thin-volume spike. Assigning modest continuation probability above 0.5 — momentum is real but capped by the recall risk and the mixed news environment.

  62. !Jun 23, 11:05 AMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    BDX is up 2.39% today, a meaningful move driven by a mix of signals. The Vizient Innovative Technology Contract for CentroVena One is a positive catalyst supporting the move. However, the voluntary recall of skin preparation products is a meaningful headwind that likely dampened what could have been a stronger rally — the net positive price action suggests the contract win is being weighted more heavily by the market. Macro context is modestly supportive: below-trend inflation expectations (T10YIE at 1.7σ below 24-month trend) favor long-duration sensitive and defensive healthcare names like BDX, as lower real rates reduce discount pressure on stable cash flow businesses. With 280 minutes remaining, there is ample time for continuation. That said, the recall overhang introduces uncertainty and could invite late-session selling or profit-taking as participants reassess the liability exposure. No strong reversal signal is present, and the move appears grounded in real news flow rather than a thin-volume spike. Assigning modest continuation probability above 0.5 — momentum is real but capped by the recall risk and the mixed news environment.

  63. ?Jun 23, 9:55 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BDX is up 1.61% today, a modest but real move. The Vizient Innovative Technology contract award for CentroVena One is a positive catalyst providing some fundamental support. The voluntary recall headline is a mild headwind but appears contained to select skin prep products — not a systemic issue — and the stock is still trading up, suggesting the market has largely digested the recall news without panic selling. The macro backdrop is mildly supportive for healthcare: 10Y inflation expectations are 1.7σ below trend, suggesting a lower-rate environment that is neutral-to-positive for a large-cap med-tech like BDX. With 350 minutes remaining there is ample time for continuation. No reversal signals are apparent — the move appears orderly rather than a sharp gap that is fading. The setup is ordinary momentum with mixed but net-positive news flow; no strong reason to expect a fade. Probability is modest given the recall overhang and the relatively small move size, but edges above the 0.5 threshold.

  64. ❖Jun 23, 6:50 AMnewsvia finnhub

    BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its BD® CentroVena One™ Insertion System has been awarded an Innovative Technology contract from Vizient®, the nation's largest provider-driven healthcare performance improvement company. This contract recognizes products with the potential to drive meaningful improvements in healthcare delivery.

  65. ❖Jun 23, 4:35 AMnewsvia finnhub

    Becton Dickinson (BDX) Issues Voluntary Recall for Select Skin Preparation Products

    Becton, Dickinson and Company (NYSE:BDX) is one of the 10 Cheap Jim Cramer Stocks to Invest In Right Now. On June 6, 2026, Becton, Dickinson and Company (NYSE:BDX) issued a nationwide voluntary recall for specific lots of its ChloraPrep™ Clear 1 mL and FREPP™ Clear 1.5 mL skin preparation applicators due to potential fungal contamination […]

  66. ❖Jun 23, 2:55 AMnewsvia finnhub

    Becton Dickinson's CentroVena One Insertion System Awarded Innovative Technology Contract From Vizient; Terms Not Disclosed

    The contract was awarded following a review by hospital experts serving on Vizient's client-led councils, and recognizes that CentroVena One™ offers differentiated capabilities through its all-in-one design with the

  67. ❖Jun 22, 9:10 AMnewsvia finnhub

    How to Approach Abbott Stock Following Its Sharp YTD Decline?

    ABT falls 29.4% YTD as respiratory testing weakness, China uncertainty and acquisition dilution pressure results and outlook.

  68. ❖Jun 22, 2:05 AMnewsvia finnhub

    3 Excellent Dividend Stocks to Buy on the Dip

    Don't wait too long to get in on these outstanding dividend payers.

  69. ❖Jun 22, 12:03 AMnewsvia finnhub

    Best Dividend Kings: June 2026

    Dividend Kings rebound in June, nearly matching SPY YTD.

  70. ❖Jun 21, 7:09 AMnewsvia finnhub

    Will CONMED’s New CFO Shift CNMD’s Financial Playbook Or Deepen Its Existing Strategy?

    On June 17, 2026, CONMED Corporation announced that John E. Gallagher will become Executive Vice President, Chief Financial Officer, and principal financial and accounting officer from July 15, 2026, succeeding Todd Garner, who will remain in an advisory role until November 2, 2026. Gallagher’s nearly three decades of finance leadership across healthcare and industrial companies, including senior roles at Certara, Cue Health, and Becton Dickinson, signals a refreshed approach to CONMED’s...

  71. ❖Jun 18, 1:30 PMnewsvia finnhub

    Global Closed System Drug Transfer Devices Market Size/Share Worth USD 3.21 Billion by 2035 at a 8.3% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)

    [220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Closed System Drug Transfer Devices Market size & share revenue was valued at approximately USD 1.47 Billion in 2025 and is expected to reach USD 1.58 Billion in 2026 and is expected to reach around USD 3.21 Billion by 2035, at a CAGR of 8.3% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are BD (Becton Dic

  72. ?Jun 17, 3:06 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BDX is down 2.59% intraday, which is a meaningful move suggesting real selling pressure. However, several factors argue against continuation: (1) Only 40 minutes remain until the forced close, leaving very limited time for the move to extend to the +3% profit target — the risk/reward window is compressed. (2) BDX is a defensive healthcare/medical device stock. The macro context shows T10Y2Y at 2.3σ below trend (flattening/near-inversion territory), which per the FRED brief is actually supportive of defensives in a bear-flattening environment — this creates a potential bid under BDX into the close as defensive rotation may absorb sellers. (3) No news catalyst identified, meaning the move could be basket selling or sector rotation that may have already run its course. (4) With a -2.59% move already in the books and no identifiable catalyst, late-session mean reversion or short covering is plausible rather than continued selling. The combination of very limited time remaining and a macro backdrop that is marginally supportive of defensives tips the probability just below the 0.5 threshold.

  73. ❖Jun 16, 9:54 AMnewsvia finnhub

    Here's Why You Should Retain BDX Stock in Your Portfolio Now

    Becton, Dickinson's MedTech focus, innovation push and strategic partnerships support growth optimism, though reimbursement uncertainty remains a key concern.

  74. ❖Jun 15, 3:24 PMnewsvia finnhub

    BofA Trims Becton Dickinson (BDX) Target as Medtech Headwinds Persist

    Becton, Dickinson and Company (NYSE:BDX) is included among the Top 10 Income Stocks with the Highest Upside Potential. On June 12, BofA lowered its price recommendation on Becton, Dickinson and Company (NYSE:BDX) to $170 from $177. It reiterated a Neutral rating on the shares. The analyst noted that the firm’s services team continues to observe […]

  75. ❖Jun 12, 2:17 PMnewsvia finnhub

    Is Becton, Dickinson and Company (BDX) A Good Stock To Buy Now?

    Is BDX a good stock to buy? We came across a bullish thesis on Becton, Dickinson and Company on The Mispricing Desk’s Substack. In this article, we will summarize the bulls’ thesis on BDX. Becton, Dickinson and Company’s share was trading at $149.99 as of June 8th. BDX’s trailing and forward P/E were 26.38 and 11.21 respectively […]

  76. ❖Jun 11, 9:20 AMnewsvia finnhub

    Is ResMed Stock Underperforming the Dow?

    While ResMed has underperformed relative to the Dow over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

  77. ❖Jun 6, 11:06 AMnewsvia finnhub

    Jim Cramer on Becton, Dickinson: “I Think You Buy Some and Then You Wait”

    Becton, Dickinson and Company (NYSE:BDX) was among the stocks on which Jim Cramer gave his opinion, as he warned that increased AI-related spending might cause near-term headwind for stocks. When a caller mentioned that they had started a position in the stock, Cramer commented: I like Becton, Dickinson. It is selling frankly at the lowest […]

  78. ❖Jun 5, 2:19 PMnewsvia finnhub

    Dividend Champion, Contender, And Challenger Highlights: Week Of June 7

    Get this week’s dividend updates for Champions, Contenders & Challengers—see hikes/cuts, upcoming ex-dividend dates and pay dates.

  79. ❖Jun 5, 9:35 AMnewsvia finnhub

    10 Health Care Stocks Whale Activity In Today's Session

  80. ✓Jun 5, 9:11 AMdecisionacted

    Agent 7 — Day Trader — decide: buy

    BDX is up 2.71% intraday, a meaningful move suggesting real institutional flow. The only headline is an ex-dividend notice, which typically attracts buyers ahead of the record date and can sustain mild upward pressure. Defensive/healthcare names like BDX can benefit from the current macro backdrop: the T10Y2Y at 0.42 (1.9σ below trend) signals a flattening curve environment that historically supports defensive sectors. With 395 minutes remaining (roughly 6.5 hours, suggesting this is early in the session), there is ample time for continuation. No reversal signals are noted, and no obvious catalyst for a fade is present. The macro environment is modestly supportive for defensives. However, the ex-dividend angle is a muted catalyst, and the move is already near the upper end of what typically sustains without a stronger fundamental driver. Assigning a modest continuation probability above 0.5 — momentum is real, backdrop is supportive, but no strong conviction signal pushes this to 0.7+.

  81. ❖Jun 5, 6:11 AMnewsvia finnhub

    Is It Smart To Buy Becton, Dickinson and Company (NYSE:BDX) Before It Goes Ex-Dividend?

    Becton, Dickinson and Company ( NYSE:BDX ) stock is about to trade ex-dividend in 3 days. The ex-dividend date occurs...

  82. ▢Jun 4, 8:00 PMjournal

    Agent 7 — Day Trader opened long 12 @ $149.56

  83. ▣Jun 4, 8:00 PMjournaltime_stop

    Agent 7 — Day Trader closed long 12 @ $151.59 (+$24.30)

    EOD forced close — day trader never carries overnight

  84. ?Jun 4, 9:35 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BDX is up 1.86% today, a meaningful but not outsized move. No specific bullish catalyst is visible in the headlines — the only recent article questions whether BDX is underperforming the healthcare sector, which is mildly bearish in tone but not a direct headwind. The macro context shows a flattening yield curve (T10Y2Y 2.1σ below trend), which is supportive for defensive healthcare names like BDX as investors rotate toward defensives in a bear-flattening environment. With 370 minutes remaining (essentially a full trading day still ahead), there is ample time for continuation. The move size is in the range where real institutional flow is likely responsible, and the absence of a negative catalyst means no obvious reversal trigger. However, the headline questioning sector underperformance and no clear positive news catalyst temper conviction. Overall, this is an ordinary momentum setup with supportive macro backdrop — probability sits modestly above 0.5 for continuation.

  85. ❖Jun 3, 11:15 PMnewsvia finnhub

    Becton, Dickinson and Company Stock: Is BDX Underperforming the Healthcare Sector?

    Although Becton, Dickinson and Company has underperformed its sector peers recently, analysts remain moderately optimistic about the stock’s prospects.

  86. ❖Jun 3, 3:32 PMnewsvia finnhub

    Lightning Round: Take a little off the table with JFrog, says Jim Cramer

    'Mad Money' host Jim Cramer weighs in on stocks including: FROG, BDX, SAN, BLZE, and FJET.

  87. ❖Jun 3, 2:57 PMnewsvia finnhub

    Cramer's lightning round: Buy Becton Dickinson

    "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

  88. ❖Jun 1, 10:07 AMnewsvia finnhub

    Is Avantor (AVTR) Elevating Quality To A Strategic Edge With Its New Regulatory Chief?

    In May 2026, Avantor, Inc. appointed Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory, giving him global responsibility for quality assurance, quality systems, and regulatory affairs across all of the company’s businesses. Porreca’s extensive background in steering complex global approvals and regulatory transformations at Getinge, Becton Dickinson, C.R. Bard, and Smith+Nephew adds experienced leadership in areas that are increasingly critical for life sciences...

  89. ❖Jun 1, 6:59 AMnewsvia finnhub

    Is Stryker Stock Underperforming the S&P 500?

    Despite Stryker’s underperformance relative to the S&P 500 Index over the past year, Wall Street analysts remain highly bullish about the stock’s prospects.

  90. ❖Jun 1, 1:03 AMnewsvia finnhub

    Becton, Dickinson: A More Streamlined Business With Mid-To-High Teens Return Potential

    Becton Dickinson expects to achieve currency-neutral revenue growth in the low single-digit range for the current fiscal year. Read more here.

  91. ❖May 31, 11:56 AMnewsvia finnhub

    Intuitive Surgical Stock: Is ISRG Underperforming the Healthcare Sector?

    Despite recent underperformance relative to the healthcare sector, analysts remain fairly bullish on Intuitive Surgical's long-term fundamentals and growth potential.

  92. ❖May 31, 9:25 AMnewsvia finnhub

    3 Dividend Kings That Earn Their Crown Every Quarter

    These 3 Dividend Kings combine decades of dividend growth with strong fundamentals, recession resistance, and long-term income potential

  93. ❖May 29, 3:36 PMnewsvia finnhub

    Sector Update: Healthcare Stocks Softer Late Afternoon

    Healthcare stocks declined late Friday afternoon, with the NYSE Healthcare Index decreasing 0.8% and

  94. ❖May 29, 8:26 AMnewsvia finnhub

    Here’s Hinde Group’s Updates on Becton, Dickinson and Company (BDX)

    Hinde Group, an investment management company, has released its first-quarter 2026 investor letter. A copy of the letter is available to download here. The portfolio delivered a gross return of 3.80% and a net return of 3.41% in the first quarter, compared to a -4.33% return for the S&P 500 Index. The first quarter began with […]

  95. ❖May 27, 8:46 AMnewsvia finnhub

    How Abbott's Diagnostics Unit Is Shaping Up Through the Rest of 2026

    ABT's Diagnostics unit witnesses mixed Q1 results as Core Lab growth offsets China weakness and softer respiratory testing demand.

  96. ❖May 27, 6:08 AMnewsvia finnhub

    Cramer’s Stop Trading: Boston Scientific

    CNBC’s Jim Cramer explains why he is keeping an eye on shares of Boston Scientific.

  97. ❖May 27, 4:43 AMnewsvia finnhub

    Best Dividend Aristocrats: May 2026

    The Dividend Aristocrats underperformed SPY YTD, returning 3.34% versus SPY's 10.39%, though 22 Aristocrats still posted double-digit gains.

  98. ❖May 25, 10:53 PMnewsvia finnhub

    Best Dividend Kings: May 2026

    Dividend growth among Kings accelerated to 3.71%, with notable increases from W.W. Grainger, Parker-Hannifin, and RLI Corp. Read more on Dividend Kings here.

  99. ❖May 25, 5:10 PMnewsvia finnhub

    BD Sharpens Urology And Infection Prevention Focus As Valuation Lags Targets

    BD (NYSE:BDX) has introduced the Elyra Thulium Fiber Laser System for kidney stone treatment, aiming to improve efficiency and flexibility in urologic procedures. The company also restated a long term global partnership with Bactiguard to broaden access to infection prevention catheter technology. Becton Dickinson sits at the intersection of medical devices, diagnostics, and interventional solutions, so updates in urology and infection prevention speak directly to its core business. The...

  100. ❖May 22, 10:13 AMnewsvia finnhub

    BD Launches Elyra Thulium Fiber Laser System for Kidney Stone Care

    BDX launches the Elyra Thulium Fiber Laser system to streamline kidney stone care and boost workflow flexibility for urology teams.

  101. ?May 21, 12:36 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BDX is down 1.72% with no attributable news headline, suggesting either broad sector selling or quiet institutional flow. The move is meaningful but below the 2-5% high-conviction threshold. Macro context shows elevated 10Y inflation expectations (2.44, +1.7σ above trend), which pressures long-duration sensitive sectors and could weigh on defensive healthcare names like BDX that carry duration-like characteristics. However, with 189 minutes remaining there is ample time for either continuation or mean reversion. No reversal pattern is evident from the data, and absence of news does not disqualify momentum. The macro backdrop provides mild incremental support for continued downside pressure on this type of name. Overall this is a borderline read — no strong reason to expect a fade, modest macro tailwind for the move direction, giving a neutral-to-slight continuation lean at 0.50.

  102. ?May 21, 10:05 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BDX is down 1.68% intraday, a meaningful but not extreme move. There are no news catalysts to explain the drop, which makes it harder to assess whether this is informed selling or noise. The macro context shows elevated 10-year inflation expectations (T10YIE at 1.7σ above trend), which pressures long-duration sensitive sectors — healthcare/medtech like BDX can be modestly affected by rate/inflation dynamics, providing a mild tailwind for continuation of the downside. However, at 340 minutes remaining (early in the session), there is ample time for either continuation or reversal. The move is not large enough to signal strong institutional conviction on its own, and without a news catalyst or clear sector rotation story, this is a borderline setup. No reversal signals are evident (no fade off highs described), so momentum favors continuation at minimum probability. Assigning 0.5 — a neutral-to-slight lean toward continuation given the macro headwind context, but insufficient evidence for higher conviction.

  103. ?May 19, 2:16 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BDX is up 3.33% intraday with no attributable headline, suggesting this is likely a delayed reaction to earnings, analyst action, or institutional accumulation rather than noise. The move is at the upper bound of the 2-5% meaningful flow range, indicating real conviction from someone with size. However, several factors temper continuation enthusiasm: (1) 89 minutes remaining is moderate — enough time for continuation but also enough for a fade if sellers emerge near session highs; (2) BDX is a healthcare/medical devices name, generally a defensive sector, which is not particularly macro-sensitive to the elevated T10YIE reading (2.48, 2.4σ above trend) — long-duration sensitive sectors are more at risk from this inflation signal, but BDX's defensive cash flows mean it is modestly affected rather than severely so; (3) no news context means we cannot confirm whether the catalyst is still actionable or already fully priced; (4) a 3.33% move into a defensively-oriented name mid-session with no news could invite profit-taking into the close. On balance, momentum favors mild continuation — the absence of a clear reversal signal and the presence of a meaningful directional move keeps the bias slightly positive, but this is not a high-conviction setup. Assigning modest probability above 0.5.

  104. ?May 19, 12:46 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BDX is up 2.82% intraday with no attributable headline, suggesting quiet but real institutional flow rather than a news spike that might fade. With 180 minutes remaining there is adequate time for continuation. However, several factors temper conviction: (1) the macro context shows 10Y inflation expectations running 2.4σ above trend, which pressures long-duration and rate-sensitive sectors — medical devices/MedTech like BDX can face headwinds when real rates or inflation expectations are elevated; (2) no news catalyst means the driver is opaque, making it harder to assess whether the flow is exhausted; (3) a ~2.82% move puts the stock near the upper bound where intraday mean-reversion risk begins to rise. Net assessment: momentum is modestly positive with no clear fade signal, so probability edges above 0.5 but without strong directional conviction.

  105. ?May 19, 10:56 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BDX is up 3.55% intraday with no attributable headline, suggesting institutional flow or a sector rotation rather than a news-driven spike. At 290 minutes remaining there is ample time for continuation, but the absence of a catalyst makes it harder to assign high conviction. The macro context shows elevated 10-year inflation expectations (T10YIE 2.4σ above trend), which is a mild headwind for long-duration sensitive names; however, BDX as a healthcare/medtech name has moderate but not extreme duration sensitivity, so this is only a partial drag. No reversal signal is evident from the data provided — the move appears directionally clean without a fade described. With a 3.55% gap already in place, the +3% profit target from current levels would require a move to roughly $151.82, which is ambitious but not unreachable intraday if momentum persists. The tight -1.5% stop limits downside. Overall: ordinary momentum setup with no strong reason to fade, warranting a modest continuation probability just above the threshold.

  106. ✓May 19, 9:28 AMdecisionacted

    Agent 4 — Dip Buyer (Frozen) — decide: buy

    BDX delivered solid Q2 performance with Barclays lifting its price target, suggesting no fundamental deterioration — the 11% drop from the 30-day high appears macro/rotation-driven rather than company-specific. The appointment of a new EVP for BD Interventional signals ongoing organizational investment. However, elevated 10-year inflation expectations (T10YIE at 2.4σ above trend) create headwinds for this large-cap, dividend-paying medtech name as rates and real yields pressure valuation multiples on long-duration assets.

  107. ▣May 18, 8:00 PMjournalstop

    Agent 6 — Options Momentum closed long 100 @ $4.50 (-$169.93)

    Stop: premium $4.50 ≤ trailing floor $5.10 (peak $6.80 × 0.75)

  108. ✓May 18, 12:20 PMdecisionacted

    Agent 4 — Dip Buyer (Frozen) — decide: buy

    BDX delivered solid Q2 results with Barclays raising its price target, suggesting the 10.4% pullback from the 30-day high is not fundamentals-driven but likely reflects broader macro pressures — notably elevated inflation expectations (T5YIE at 2.5σ above trend) driving sector rotation away from defensive healthcare names. The appointment of a new EVP signals management continuity and strategic investment, not distress. As a large-cap medical device company with stable recurring revenue, BDX has historically recovered from macro-driven selloffs within a 90-day window.

  109. ✓May 18, 9:25 AMdecisionacted

    Agent 8 — Dip Buyer (Peer-Aware) — decide: buy

    BDX is a large-cap medical device company with a long track record of financial stability. The most recent news confirms a solid Q2 performance with a Barclays price target lift, suggesting the drop is not driven by fundamental deterioration but likely by sector-wide weakness — Health Care ranks 10th of 11 sectors in 30-day relative strength, down 13.87 pts vs. SPY, indicating this is a macro/sector-driven move rather than an idiosyncratic impairment. Options flow shows a bullish skew with a P/C ratio of 0.57 and call volume nearly double put volume, providing mild confirmation of dip-buying interest.

  110. ✓May 18, 9:00 AMdecisionacted

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    BDX passes the hard veto check: no imminent earnings, no fundamental deterioration flagged in filings, and no sector freefall combined with acute macro stress. Signal scoring: (+1) sector is broadly underperforming — Health Care ranks 10 of 11 by 30-day relative strength and is down 13.87pts vs SPY over 30 days, suggesting the dip is sector-wide rather than idiosyncratic to BDX; (+1) no earnings within visible window provides a clean 90-day runway; (+1) options flow is constructive with a P/C ratio of 0.57 (calls dominant) on a dipping stock, a mild informed-buying signal; (+1) Barclays lifted its price target following solid Q2 results, indicating no fundamental deterioration — in fact, a positive fundamental read-through. Negative signals: (-1) the 10-day BDX drop of 10.3% is below the 15% threshold for a strong mean-reversion flag, limiting that bonus; the 10Y at 4.47% is just under the 4.5% headwind threshold for a defensive/value name like BDX, so neutral (0); VIX at 17.26 is at the 50th percentile, no penalty; no insider sales or unusual put activity. No cluster insider buy is present, so the net score does not reach the high-conviction tier. Net signal score: approximately +3, supporting a buy. The broad market is weak today (SPY -1.2%, IWM -2.4%), which introduces short-term headwind, and inflation expectations (T5YIE at 2.7, 2.5σ above trend) add modest macro uncertainty. These reduce conviction slightly. Anchoring at the ~57% base rate for S&P 500 names with a 10%+ dip and no fundamental impairment, the constructive options flow, positive Q2 results, and sector-wide rather than idiosyncratic weakness provide modest upward adjustment, partially offset by today's broad risk-off tone and elevated inflation expectations. A new executive appointment (BD Interventional president) is strategically neutral to mildly positive.

  111. ?May 18, 8:54 AMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    BDX is a diversified medical technology company with a long track record of stable revenues, recurring demand in diagnostics and medication delivery, and investment-grade credit quality — no headlines or filings in the window suggest fundamental deterioration, making the 10.3% pullback appear more likely attributable to macro rotation or sector pressure than company-specific bad news. However, the elevated 5-year breakeven inflation print (2.7%, 2.5σ above trend) signals a risk-off, rising-rate-expectation environment that weighs on lower-growth, bond-proxy-like medtech names such as BDX. With no catalyst visible to reverse the macro headwind within 90 days, confidence in a full mean-reversion to the 30-day high is moderate at best.

  112. ❖May 18, 6:50 AMnewsvia finnhub

    Peter Menziuso Named EVP and President, BD Interventional

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Peter Menziuso has been named executive vice president and president, BD Interventional, effective June 1.

  113. ?May 16, 6:35 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash

    Wanted to buy but only $6.08 cash available; close=$143.47.

  114. ?May 16, 10:05 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BDX is down 10.3% from its 30-day high at $143.47, but the evidence base is nearly empty: no recent news, no SEC filings, no insider activity, no options flow, and no upcoming earnings catalyst to anchor a thesis. Without knowing the cause of the decline, it is impossible to assess whether the drop reflects idiosyncratic company issues (a fundamental deterioration) or broader sector/market weakness. The macro backdrop adds headwinds: the broad market is broadly weak today (SPY -1.20%, IWM -2.41%), the 10Y yield at 4.47% is near the elevated threshold that pressures dividend-oriented healthcare names, and 5Y inflation breakevens printing 2.7 (2.5 sigma above trend) suggest a reflationary regime that historically favors energy and commodities over defensive healthcare. VIX at the 50th percentile is neutral but the day's VXX +0.80% signals mild risk-off momentum. No sector outperformance data is available to determine if this is idiosyncratic. The total absence of insider buying, unusual call flow, or any positive catalyst means there is no confirming signal to support a counter-trend entry. Conservative discipline requires passing when the thesis rests entirely on price action without corroborating evidence.

  115. ?May 16, 9:19 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    BDX has declined 10.3% from its 30-day high to $143.47, which on the surface appears to offer a value entry. However, the evidence base is notably thin: no recent news headlines, no SEC filings, no insider activity, and no options flow data are available to corroborate a thesis. Without any insider cluster buying or unusual call flow to suggest informed accumulation, the dip lacks confirmation signals. The broad market is under pressure today (SPY -1.20%, IWM -2.41%), indicating the decline may partly reflect macro headwinds rather than a stock-specific mispricing. The macro backdrop is mixed-to-cautious: the 10Y yield at 4.47% is close to the structural headwind threshold of ~4.5%, VIX at the 50th percentile is neutral, and the 5Y breakeven inflation at 2.7% (2.5σ above trend) suggests inflation expectations are re-anchoring higher, which is a headwind for healthcare equipment names like BDX that carry meaningful duration in their valuation. The 2s10s spread is slightly positive (+0.47pp), which removes one concern, but does not offset the other pressures. No earnings catalyst or sector rotation data is available to improve conviction. The absence of evidence is not evidence of safety here; with no supporting signals and a challenging macro backdrop, the risk/reward for a 90-day swing trade is insufficiently favorable.

  116. ?May 16, 9:01 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    BDX is a large-cap, diversified medical technology company with a historically stable business and long dividend track record, suggesting no fundamental deterioration is evident from the available data. However, the evidence base is extremely thin — no news, no filings, no insider buying, and no options flow — making it impossible to distinguish between an idiosyncratic drop and a macro/sector-driven pullback. The broad market is under meaningful pressure today (SPY -1.20%, IWM -2.41%, VXX elevated), and elevated 5-year inflation expectations (T5YIE at 2.5σ above trend) create a risk-off headwind that is unlikely to favor a defensive healthcare name rebounding quickly.

  117. ?May 16, 9:00 AMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    BDX is a diversified medical technology company with a long track record of stable revenues, recurring demand in diagnostics and medication delivery, and investment-grade credit quality — no headlines or filings in the window suggest fundamental deterioration, making the 10.3% pullback appear more likely attributable to macro rotation or sector pressure than company-specific bad news. However, the elevated 5-year breakeven inflation print (2.7%, 2.5σ above trend) signals a risk-off, rising-rate-expectation environment that weighs on lower-growth, bond-proxy-like medtech names such as BDX. With no catalyst visible to reverse the macro headwind within 90 days, confidence in a full mean-reversion to the 30-day high is moderate at best.

  118. ?May 16, 8:58 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BDX is a well-established medical devices and diagnostics company with a long operating history and generally stable fundamentals, suggesting the underlying business is likely sound absent any disqualifying evidence. However, the evidence base here is nearly empty — no recent news, no SEC filings, no insider buying, and no options flow — making it impossible to distinguish whether the 10.3% pullback from the 30-day high is idiosyncratic stress or macro-driven. The broader market is in a risk-off session today (SPY -1.20%, IWM -2.41%, VXX +0.83%), and elevated 5-year inflation expectations (T5YIE at 2.5σ above trend) create a headwind for valuation multiples in rate-sensitive healthcare equities, reducing confidence in a near-term mean reversion.

  119. ❖May 16, 5:54 AMnewsvia finnhub

    Becton Dickinson (BDX) Delivers Solid Q2 Performance, Barclays Lifts Target

    Becton, Dickinson and Company (NYSE:BDX) is included among the 11 Best Rising Dividend Stocks to Buy Right Now. On May 11, Barclays raised its price recommendation on Becton, Dickinson and Company (NYSE:BDX) to $204 from $202. It reiterated an Overweight rating on the shares following the company’s fiscal Q2 results. The firm said Becton delivered […]

  120. ?May 15, 6:37 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BDX is a well-established medical devices and diagnostics company with a long operating history and generally stable fundamentals, suggesting the underlying business is likely sound absent any disqualifying evidence. However, the evidence base here is nearly empty — no recent news, no SEC filings, no insider buying, and no options flow — making it impossible to distinguish whether the 10.3% pullback from the 30-day high is idiosyncratic stress or macro-driven. The broader market is in a risk-off session today (SPY -1.20%, IWM -2.41%, VXX +0.83%), and elevated 5-year inflation expectations (T5YIE at 2.5σ above trend) create a headwind for valuation multiples in rate-sensitive healthcare equities, reducing confidence in a near-term mean reversion.

  121. ?May 15, 6:33 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BDX is a well-established medical devices and diagnostics company with a long operating history and generally stable fundamentals, suggesting the underlying business is likely sound absent any disqualifying evidence. However, the evidence base here is nearly empty — no recent news, no SEC filings, no insider buying, and no options flow — making it impossible to distinguish whether the 10.3% pullback from the 30-day high is idiosyncratic stress or macro-driven. The broader market is in a risk-off session today (SPY -1.20%, IWM -2.41%, VXX +0.83%), and elevated 5-year inflation expectations (T5YIE at 2.5σ above trend) create a headwind for valuation multiples in rate-sensitive healthcare equities, reducing confidence in a near-term mean reversion.

  122. ?May 15, 6:24 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — analyze: fail

    Analyze call failed: Anthropic 400: {"type":"error","error":{"type":"invalid_request_error","message":"Your credit balance is too low to access the Anthropic API. Please go to Plans & Billing to upgrade or purchase credits."},"request_i

  123. ?May 15, 6:23 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — analyze: fail

    Analyze call failed: Anthropic 400: {"type":"error","error":{"type":"invalid_request_error","message":"Your credit balance is too low to access the Anthropic API. Please go to Plans & Billing to upgrade or purchase credits."},"request_i

  124. ?May 15, 6:15 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — analyze: fail

    Analyze call failed: Anthropic 400: {"type":"error","error":{"type":"invalid_request_error","message":"Your credit balance is too low to access the Anthropic API. Please go to Plans & Billing to upgrade or purchase credits."},"request_i

  125. ?May 15, 3:38 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — analyze: fail

    Analyze call failed: Anthropic 400: {"type":"error","error":{"type":"invalid_request_error","message":"Your credit balance is too low to access the Anthropic API. Please go to Plans & Billing to upgrade or purchase credits."},"request_i

  126. ✓May 14, 3:43 PMdecisionacted

    Agent 6 — Options Momentum — decide: buy

    PUT on BDX — 5-day return -5.87% with close below 20-day MA ($149.85). IV 37.0%. Sized 1 contract(s) at $6.20 premium.

  127. ▢May 13, 8:00 PMjournal

    Agent 6 — Options Momentum opened long 100 @ $6.20

← Back to dashboard